



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 25 Sep 2018 (#28)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 30 days before the submission date.

Contact: RGMO Pre-Awards cdevries@sun.ac.za

Important Notices

- **Notice of Clarification: Research Strategy page limit for PA-18-794, AHRQ Small Research Grant Program (R03) ([NOT-HS-18-016](#))**

1. Limited Competition for the Continuation of the Childhood Liver Disease Research Network (ChiLDReN) Clinical Centers (Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink: ([RFA-DK-18-501](#))

Type: U01

Application Due Date: 20 Nov 2018. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this funding opportunity announcement (FOA) is to continue the support the Childhood Liver Disease Research Network (ChiLDReN) to conduct clinical and translational research on rare pediatric liver diseases. ChiLDReN is composed of a Scientific and Data Coordination Center (SDCC) and Clinical Centers (CC). ChiLDReN will continue clinical and translational research on pediatric liver diseases that include: Biliary Atresia; Alagille syndrome; alpha-1-antitrypsin deficiency; Progressive Familial Intrahepatic Cholestasis syndromes; Bile acid synthesis defects; Mitochondrial hepatopathies; Idiopathic Neonatal Hepatitis; Cystic Fibrosis Liver Disease; and primary sclerosing cholangitis.

Budget: The NIDDK intends to commit \$ 6.5 million in FY 2019 to support two related approaches to the continuation of the ChiLDReN Network as embodied in RFA-DK-18-501 and RFA-DK-18-502. It is expected that up to 14 awards will be supported in FY 2019 in total under these two RFAs. Initial award may be no more than \$800,000 direct costs per year may be requested. Based on project data provided in the annual RPPR, some awards may be adjusted (e.g., reduced or increased above the initial budget threshold) to accommodate recruitment and other scientific and patient care needs associated with the Network operations and approved scientific projects. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

2. BRAIN Initiative Cell Census Network (BICCN) Scalable Technologies and Tools for Brain Cell Census (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: ([RFA-MH-19-148](#))

Type: R01

Application Due Date: January 22, 2019 and January 24, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) intends to accelerate the integration and use of scalable technologies and tools to enhance brain cell census research, including the development of technology platforms and/or resources that will enable a swift and comprehensive survey of brain cell types and circuits. Applications are expected to address limitations and gaps of existing technologies/tools as a benchmark against which the improvements or competitive advantages of the proposed ones will be measured. The improvements include throughput, sensitivity, selectivity, scalability, spatiotemporal resolution and reproducibility in cell census analyses. The projects funded under this FOA will align with the overarching goals of the BRAIN Initiative Cell Census Network (BICCN) and are expected to enable the generation of a substantial amount of cell census data using the proposed technologies or via collaboration with the BICCN.

Budget: Issuing IC and partner components intend to commit an estimated total of \$6 M to fund 4-8 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 3 years.

3. BRAIN Initiative Cell Census Network (BICCN) Specialized Collaboratory on Human and Non-Human Primate Brain Cell Atlases (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(RFA-MH-19-149\)](#)

Type: U01

Application Due Date: January 22, 2019 ; January 24, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) intends to support a group of Specialized Collaboratories that will adopt scalable technology platforms and streamlined workflows to accelerate progress towards establishing comprehensive molecular and anatomical reference cell atlases of human brain and/or non-human primate brains. A central goal of this FOA is to build a brain cell census resource that can be widely used throughout the research community.

Budget: Issuing IC and partner components intend to commit an estimated total of \$8 M for FY 19 to fund 3-6 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 3 years.

4. Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimers Dementia (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(RFA-MH-19-510\)](#)
[\(RFA-MH-19-511\)](#)

Type: R01
R21

Application Due Date: November 19, 2018 and March 19, 2019. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings from such research are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS, and may provide insight into novel targets for interventions that might alleviate some burden associated with these symptoms or suggest strategies for prevention of the development of NPS as related to AD or ADRD.

Budget: NIH intends to fund an estimate of 5-7 awards, corresponding to a total of \$ 6,000,000, for fiscal year 2019 for this and the companion R21 announcement. Future year amounts will depend on annual appropriations. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. **R21-** Direct costs are limited to \$275,000 over a two-year project period, with no more than \$200,000 in direct costs allowed in any single year.

5. Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(RFA-NS-18-043\)](#)
[\(RFA-NS-18-042\)](#)

Type: R01
R21

Application Due Date: November 27, 2018; February 11, 2019; July 11, 2019; November 12, 2019. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This R21 NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of pain target discovery and validation projects. These studies may involve considerable risk but may lead to a breakthrough in a pain treatment.

Budget: Issuing IC and partner components intend to issue 8-10 awards in 2019. Awards issued under this FOA are part of funds set aside to support the HEAL (Helping to End Addiction Long-term) initiative. **R01** - Application budgets are not limited but need to reflect the actual needs of the proposed project. Total project duration of no more than 5 years. **R21** - The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

6. Analytical and/or Clinical Validation of a Candidate Biomarker for Pain (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(RFA-NS-18-046\)](#)

Type: R61/R33

Application Due Date: November 27, 2018; March 7, 2019; November 25, 2019; March 12, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the validation of strong candidate biomarkers and endpoints for pain that can be used to facilitate the development of non-opioid pain therapeutics from discovery through Phase II clinical trials. Specifically, the focus of this FOA is on advanced analytical and clinical validation of pain biomarkers, biomarker signatures, and/or endpoints using retrospective and/or prospective methods. It is assumed that: 1) a candidate biomarker has already been identified, 2) assay technology has already been developed, and 3) a working hypothesis regarding Context of Use is in place. Research supported by this FOA will ultimately demonstrate that biomarker or endpoint change is reliably correlated with variables such as clinical outcome, pathophysiologic subsets of pain, therapeutic target engagement or response to a pain therapeutic; in addition, biomarker response will demonstrate specificity to the pain condition or therapeutic as demonstrated at multiple clinical sites. The goal of this FOA is to facilitate the advancement of robust and reliable biomarkers, biomarker signatures and endpoints of pain to application in clinical trials (Phase II clinical trials and beyond) and in the spectrum of clinical practice.

Budget: Issuing IC and partner components intend to issue 8-10 awards in 2019. Awards issued under this FOA are part of funds set aside to support the HEAL (Helping to End Addiction Long-term) initiative. Application budgets are not limited but need to reflect the actual needs of the proposed project. The R61 phase can be from 1-3 years and the R33 phase can be 1-4 years, with a total project duration of no more than 5 years.

7. Characterization of Mycobacterial Induced Immunity in HIV-infected and Uninfected Individuals (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: ([PAR-18-923](#))

Type: R21

Application Due Date: January 14, 2019; January 14, 2020; January 14, 2021 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support innovative studies to identify and understand the immunological responses that mediate protection from Mycobacterium tuberculosis (Mtb) infection or following vaccination with Bacillus Calmette-Guérin (BCG) or investigational vaccines. Studies may focus on any stage of mycobacterial infection and may include HIV-infected or uninfected individuals. Development of novel functional assays to assess host response and inclusion of immune profiling and systems biology approaches are encouraged. This FOA seeks to stimulate innovative research in deciphering immune mechanisms in humans required for protection from Mtb infection or tuberculosis (TB) disease, or induced by TB vaccines, that go beyond what have traditionally been investigated in TB.

Budget: Application budgets are limited to \$275,000 direct costs over two years, with no more than \$200,000 direct costs being requested in a single year.

8. High-Priority Areas for Research Leveraging electronic health records (EHR) and Large-Scale Data (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: ([PAR-18-929](#))

Type: R01

Application Due Date: 21 November 2018 and then [Standard dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages research project grant (R01) applications to leverage large-scale, real-world data from electronic health records (EHRs) from a variety of systems (e.g., the Department of Defense (DOD), Department of Veterans Affairs (VA), Centers for Medicare and Medicaid Services administrative claims, as well as public or private health care systems and networks) to understand risk, onset, course, and impact of treatments and services for mental and neurological disorders and to identify promising new mental health and neurological disorders research. There is particular interest in leveraging EHRs and administrative data to 1) understand and improve the treatment of post traumatic psychopathology, including posttraumatic stress disorder, depression, traumatic brain injury (TBI), and risk for suicide; and 2) characterize post-trauma multi-symptom recovery trajectory patterns of TBI, that may include post traumatic stress disorder, depression, cognitive impairment, pain, substance abuse disorder and risk for suicide. NIMH also invites innovative approaches to use EHR and administrative data to understand risk, onset, course, and impact of treatments and services for mental disorders more broadly.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

9. Development and Optimization of Tasks and Measures for Functional Domains of Behavior (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: ([PAR-18-930](#))

Type: R01

Application Due Date: [Standard dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support the development and optimization of tasks and/or measures for constructs pertaining to functional aspects of behavior or cognitive/affective processes, for use in laboratory or population-based studies, clinical trials outcomes, or related research. This FOA encourages research that will result in the availability of tasks and measures that demonstrate: (1) good validity as a measure of a specific construct; (2) robust measurement properties; and (3) suitability for use across diverse participants.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The total project period may not exceed 5 years.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)